A Phase I Single Ascending Dose (SAD) Trial of SNDX-6352 Assessing the Safety, Pharmacokinetics and Pharmacodynamics of the Anti-CSF-1R Monoclonal Antibody (SNDX-6352) in Healthy Volunteers

Trial Profile

A Phase I Single Ascending Dose (SAD) Trial of SNDX-6352 Assessing the Safety, Pharmacokinetics and Pharmacodynamics of the Anti-CSF-1R Monoclonal Antibody (SNDX-6352) in Healthy Volunteers

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs UCB 6352 (Primary)
  • Indications Cancer; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Aug 2017 Status changed from recruiting to active, no longer recruiting, according to a Syndax Pharmaceuticals media release.
    • 02 Mar 2017 According to a Syndax Pharmaceuticals media release, company expects to present data at a scientific congress in the fourth quarter of 2017.
    • 10 Nov 2016 Status changed from planning to recruiting, according to a Syndax Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top